Advertisement


Akihiro Ohba, MD, on Biliary Tract Cancer: New Findings on Fam-Trastuzumab Deruxtecan-nxki

2022 ASCO Annual Meeting

Advertisement

Akihiro Ohba, MD, of Japan’s National Cancer Center Hospital, discusses phase II data from the HERB trial on fam-trastuzumab deruxtecan-nxki, which showed activity in patients with HER2-expressing unresectable or recurrent biliary tract cancer (Abstract 4006).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The HERB trial is an investigator-initiated, multicenter, single-arm Phase II trial which evaluate the efficacy and the safety of trastuzumab deruxtecan, T-DXd, in patient with HER2-expressing biliary tract cancers. In 2016, when we began to design this study, there were no effective second-line chemotherapy regiments and no effective targeted therapies for biliary tract cancers. Moreover, even breast and gastric cancers, T-DXd did not have strong evidence, but the early efficacy signs of T-DXd in breast cancer and the HER2-positive rate in biliary tract cancer made us decide to conduct this trial. Before we ran the trial, we examined the tissue sample of more than 400 biliary tract cancer cases by HER2 testing and found that HER2 expression patterns were more similar to gastric cancer than breast cancer. We used the diagnostic criterion for this trial. Patient was screened in 30 Japanese centers taking part in the SCRUM-Japan project and the trial was conducted in five of these 30 centers. A key inclusion criteria was histologically confirmed unresectable or recurrent biliary tract cancer, centrally confirmed HER2-expressing status and refractory or intolerant to treatment, including gemcitabine. The primary endpoint was confirmed objective response rate in HER2-positive patient by blinded independent central review, BICR. During my year, we enrolled 32 patient, 24 HER2-positive, and eight were HER2-low-expressing. Two ineligible patients were excluded from the efficacy analysis. Of the 22 HER2-positive eligible patients, the primary endpoint of the confirmed objective response rate was 36.4%. Among the eight HER2-low-expressing patients, one patient achieved a partial response. The duration of response, progression-free survival and overall survival, was longer than we expected. In terms of adverse events, the most common adverse events were hematological toxicities such as anemia and neutrophil count decreased and white blood cell count decreased. They were more frequent than in clinical trials of T-DXd in other cancer types. Interstitial lung disease occurred in 25% of patient, including two grade-five cases. Also, we could not find obvious risk factors. We should pay attention to all this when we're using this drug, especially for biliary tract cancers. We think that T-DXd showed promising activity in HER2-expressing biliary tract cancers. Further evaluations are needed to confirm these findings in this patient population. On the other hand, such a large-scale trial is difficult for a limited population of HER2-positive biliary tract cancers, and we also discussed the way of drug approval based on the result of this study. I hope that such an effective drug will be available in our clinical practice.

Related Videos

Bladder Cancer

Sumanta K. Pal, MD, on Urothelial Carcinoma: New Results on Cabozantinib Plus Atezolizumab

Sumanta K. Pal, MD, of City of Hope National Medical Center, discusses findings from the COSMIC-021 study, which showed that cabozantinib plus atezolizumab demonstrated encouraging clinical activity with manageable toxicity in patients with inoperable locally advanced or metastatic urothelial carcinoma. The combination was administered as first-line therapy in cisplatin-based chemotherapy–eligible and –ineligible patients and as second- or later-line treatment in those who received prior immune checkpoint inhibitors (Abstract 4504).

Michael J. Overman, MD, and Takayuki Yoshino, PhD, MD, on Colorectal Cancer: Phase III Data on Panitumumab or Bevacizumab Plus mFOLFOX6

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and Takayuki Yoshino, PhD, MD, of the National Cancer Center Hospital East, Japan, discuss results from the PARADIGM trial, the first prospective study to test the superiority of panitumumab vs bevacizumab in combination with standard doublet first-line chemotherapy for patients with RAS wild-type and left-sided metastatic colorectal cancer. The study showed that panitumumab improved overall survival in combination with mFOLFOX6, which may establish a standard first-line combination regimen for this population (Abstract LBA1).

Supportive Care
Symptom Management

Sriram Yennu, MD, on Cancer-Related Fatigue: Is Open-Labeled Placebo an Effective Treatment?

Sriram Yennu, MD, of The University of Texas MD Anderson Cancer Center, discusses the placebo response in patients with advanced cancer and cancer-related fatigue. His latest findings show that open-labeled placebo was efficacious in reducing cancer-related fatigue and improving quality of life in fatigued patients with advanced cancer at the end of 1 week. The improvement in fatigue was maintained for 4 weeks (Abstract 12006).

Breast Cancer
Immunotherapy

Ann H. Partridge, MD, MPH, and Ian E. Krop, MD, PhD, on Metastatic Breast Cancer: New Early Data on Patritumab Deruxtecan

Ann H. Partridge, MD, MPH, Dana-Farber Cancer Institute, and Ian E. Krop, MD, PhD, of Yale Cancer Center, discuss phase I/II findings on patritumab deruxtecan, a HER3-directed antibody-drug conjugate, in patients with HER3-expressing metastatic breast cancer. A pooled analysis showed antitumor activity in women with HR-positive/HER2-negative and HER2-positive advanced disease, as well as triple-negative breast cancer (Abstract 1002).

Breast Cancer
Immunotherapy

Lisa A. Carey, MD, and Shanu Modi, MD, on Breast Cancer: Is T-DXd a Potential New Standard of Care for HER2-Low Disease?

Lisa A. Carey, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center, and Shanu Modi, MD, of Memorial Sloan Kettering Cancer Center, discuss the phase III findings from the DESTINY-Breast04 trial, which compared fam-trastuzumab deruxtecan-nxki (T-DXd) vs treatment of physician’s choice (TPC) in patients with HER2-low unresectable and/or metastatic breast cancer. T-DXd is the first HER2-targeted therapy to demonstrate clinically meaningful improvement in progression-free and overall survival compared with TPC in this patient population, regardless of hormone receptor or immunohistochemistry status or prior use of CDK4/6 inhibitors (Abstract LBA3).

Advertisement

Advertisement




Advertisement